REAL-ASE Study

We have reached an exciting milestone in the UK: Yesterday, the first patient in the REAL-ASE study (Real World Testing and Cost-effectiveness Analysis of Subcutaneous EEG) had the 24/7 EEG™ SubQ implanted. The implantation took place at King’s College London.

Another 32 people living with epilepsy will get the implant inserted for 6 months to record EEG data day and night to detect electrographic seizures. The overall aim of the study is to investigate the clinical value and the health economics of the 24/7 EEG SubQ solution. The research group believes that this research will be key in improving seizure outcome measurement in epilepsy and that it ultimately will provide new standard of care for the patients and reduce the costs.

The REAL-ASE study is a multicentre, observational cohort study of the 24/7 EEG SubQ solution for ultra long-term subcutaneous EEG monitoring. It is a joint collaboration between King’s College London and UNEEG medical with Prof. Mark Richardson and Jonas Duun-Henriksen being co-lead investigators.

The study has been made possible by a £1.82 million grant from the i4i Challenge Awards Call from the National Institute for Health and Care Research (NIHR).

More highlights

We break new ground in epilepsy. UNEEG medical A/S is an entrepreneurial and ambitious company specializing in providing the epilepsy community with more accurate knowledge of seizures to support improvement in epilepsy care, ultimately aiming at improving patients’ quality of life. Our unique subcutaneous EEG solution for remote monitoring of brain activity was CE marked in 2019.

CAUTION – Investigational device in the US. Limited by Federal law to investigational use.

UNEEG medical was founded in 2005 in Denmark and now has subsidiaries in Germany, the UK, Austria and the US. UNEEG medical currently employs about 40 people representing various cultures, backgrounds, skills, and years of experience.

REAL-ASE Study

Search